Dermatomyositis and polymyositis (myositis) trials in China

In China 38 Also abroad 124

38 trials · From ClinicalTrials.gov, checked 13 November 2026. Ask the study team whether a trial fits you.

Early phase 1Taking people
An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases
Where
Shanghai
Age
18 years to 70 years
People
20
Run by
Shanghai Cell Therapy Group Co.,Ltd
See details and how to joinNCT07174843
Phase 3Not yet taking people in China
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
Where
Beijing, Chongqing, Dongguan, Guangzhou, Hefei, Luoyang, Nanchang, Nanjing, Shanghai, Wenzhou, Wuhan, Xi'an
Age
18 years and over
People
270 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00
Phase 1Taking people
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
Where
Beijing, Shanghai, Wuhan, Zhengzhou
Age
18 years to 70 years
People
72 worldwide
Run by
AstraZeneca
See details and how to joinNCT06916806 · EU 2024-519015-34-00
Phase 3Enrolling by invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Where
Beijing, Chengdu, Guangzhou, Nanjing, Shanghai, Shenyang, Zhengzhou
Age
18 years and over
People
240 worldwide
Run by
argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00
Phase 1/2Taking people
Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases
Where
Tianjin
Age
18 years to 60 years
People
27
Run by
Tianjin Medical University General Hospital
See details and how to joinNCT07022197
Phase 3Taking people
A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
Where
Beijing, Chongqing, Dongguan, Guangzhou, Hangzhou, Hengyang, Jining, Nanjing, Shanghai, Shijiazhuang, Wenzhou, Zhengzhou
Age
18 years to 75 years
People
240 worldwide
Run by
AstraZeneca
See details and how to joinNCT06455449
Early phase 1Taking people
Clinical Study of BCT301 Cell Injection Therapy for Refractory Autoimmune Diseases
Where
Beijing
Age
18 years to 80 years
People
10
Run by
Peking University Third Hospital
See details and how to joinNCT07301164
Phase 3Taking people
A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
Where
Beijing, Cangzhou, Changsha, Chengdu, Dongguan, Guangzhou, Hangzhou, Hefei, Kunming, Nanchang, Nanjing, Shanghai, Tianjin
Age
18 years and over
People
318 worldwide
Run by
Pfizer
See details and how to joinNCT05895786 · EU 2022-502739-20-00
Phase 3Taking people
A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
Where
Beijing, Hefei, Kunming, Nanchang, Shanghai
Age
18 years and over
People
211 worldwide
Run by
Pfizer
See details and how to joinNCT06698796 · EU 2024-514648-10-00
No phaseTaking people
Biomarkers in Autoimmune Disease of Nervous System
Where
Wuhan
Age
18 years and over
People
50,000
Run by
Tongji Hospital
See details and how to joinNCT06502015
Phase 1Taking people
BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy
Where
Chengdu
Age
18 years to 60 years
People
10
Run by
iCell Gene Therapeutics
See details and how to joinNCT07715136
Early phase 1Not yet taking people in China
CD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune Diseases
Where
Shanghai
Age
18 years to 70 years
People
30
Run by
Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT07596680
Early phase 1Taking people
MTS109 in Patients With Refractory Autoimmune Diseases
Where
Shanghai
Age
18 years to 65 years
People
15
Run by
Shanghai Changzheng Hospital
See details and how to joinNCT07526350
Early phase 1Not yet taking people in China
RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases
Where
Hangzhou, Nanjing
Age
5 years to 20 years
People
30
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07674147
Phase 1Taking people
Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Where
Wuhan
Age
18 years to 75 years
People
6
Run by
Tongji Hospital
See details and how to joinNCT07526493
No phaseTaking people
Exploratory Clinical Study of Anti-CD19/BCMA Universal CAR-T Cell Injection for the Treatment of Refractory Autoimmune Diseases
Where
Nanjing
Age
18 years to 70 years
People
72
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07558850
Early phase 1Taking people
A Study of CC312 for Relapsed/Refractory Autoimmune Diseases
Where
Deyang
Age
18 years to 65 years
People
6
Run by
CytoCares Inc
See details and how to joinNCT07193810
Early phase 1Taking people
Clinical Study on Targeted CD19 or CD19-BCMA CAR-T Therapy for Autoimmune Diseases
Where
Bengbu
Age
18 years to 70 years
People
20
Run by
Nanjing Bioheng Biotech Co., Ltd.
See details and how to joinNCT06548607
Phase 1Not yet taking people in China
YTS109 in Pediatric Relapsed/Refractory Autoimmune Diseases
Where
Shanghai
Age
5 years to 18 years
People
12
Run by
Children's Hospital of Fudan University
See details and how to joinNCT07439029
Phase 1Taking people
A Study of LUCAR-G79D in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE) and Idiopathic Inflammatory Myopathies (r/r IIM)
Where
Bengbu, Changsha, Guangzhou, Nanchang, Xuzhou
Age
18 years to 70 years
People
38
Run by
Nanjing Legend Biotech Co.
See details and how to joinNCT07331272
No phaseTaking people
RCT of Tocilizumab for Anti-MDA5+DM
Where
Beijing
Age
18 years to 65 years
People
110
Run by
Peking Union Medical College Hospital
See details and how to joinNCT07377058
No phaseNot yet taking people in China
Tongji NADs Cohort
Where
Wuhan
Age
18 years to 80 years
People
1,550
Run by
Tongji Hospital
See details and how to joinNCT07333196
Phase 1Taking people
CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Where
Tianjin
Age
18 years and over
People
12
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07315087
Early phase 1Taking people
GC012F Injection in Refractory Idiopathic Inflammatory Myopathy
Where
Wuhan
Age
18 years to 70 years
People
12
Run by
Daishi Tian
See details and how to joinNCT07086404
No phaseTaking people
Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
Where
Hangzhou
Age
18 years to 65 years
People
15
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06614270